Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition
Open Access
- 1 January 2010
- journal article
- review article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 28 (1), 5-10
- https://doi.org/10.2337/diaclin.28.1.5
Abstract
IN BRIEF: This article reviews the history of phlorizin, the role of the kidney in glucose regulation, and the modulation of that regulatory system via pharmacological means. It also offers a discussion of the results of clinical trials of the most salient sodium glucose co-transporter inhibitor to date: dapagliflozin.Keywords
This publication has 17 references indexed in Scilit:
- Dapagliflozin for the Treatment of Type 2 DiabetesAnnals of Pharmacotherapy, 2009
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin SensitizersDiabetes Care, 2009
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implicationsKidney International, 2009
- Glucose Control by the Kidney: An Emerging Target in DiabetesAmerican Journal of Kidney Diseases, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes MellitusEndocrine Practice, 2008
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.JCI Insight, 1998
- Renal glucose threshold variations with age.BMJ, 1967